Omslagsbillede

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation

Show other versions (2)

<div class="page" title="Page 4"><div class="section"><div class="layoutArea"><div class="column"><p><span>New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in p...

Fuld beskrivelse

Saved in:

Bibliografiske detaljer
Hovedforfatter:	article Editorial (Author)
Format:	Bog
Udgivet:	Столичная издательская компания, 2015-11-01T00:00:00Z.
Fag:	article
Online adgang:	Connect to this object online.
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Lignende værker

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
af: article Editorial
Udgivet: (2015)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
af: article Editorial
Udgivet: (2015)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
af: Kevin Bowrin, et al.
Udgivet: (2020)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
af: Waqar shamim, et al.
Udgivet: (2022)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
af: S. V. Nedogoda, et al.
Udgivet: (2017)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
af: Noppaket Singkham, et al.
Udgivet: (2022)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
af: Robyn Konicki, et al.
Udgivet: (2020)

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
af: Chen G, et al.
Udgivet: (2024)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
af: Huamin Ding, et al.
Udgivet: (2024)

Rivaroxaban in atrial fibrillation cardioversion: an update
af: Lavalle C, et al.
Udgivet: (2019)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
af: Joseph M. Harburger, et al.
Udgivet: (2012)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
af: I. Yu. Koroleva, et al.
Udgivet: (2016)

Is There Association Between Changes in eGFR Value and the Risk of Permanent Type of Atrial Fibrillation? - Analysis of Valvular and Non-Valvular Atrial Fibrillation Population
af: Elzbieta Mlodawska, et al.
Udgivet: (2014)

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation
af: A. S. Kolbin, et al.
Udgivet: (2023)

Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice
af: N. M. Vorobyeva, et al.
Udgivet: (2018)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
af: M. Yu. Gilyarov
Udgivet: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
af: M. Yu. Gilyarov
Udgivet: (2015)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
af: Turpie AGG
Udgivet: (2014)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
af: A. D. Erlikh
Udgivet: (2020)

Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation
af: Semira Abdi Beshir, et al.
Udgivet: (2018)

Real-world outcomes of anticoagulant prescription in anticoagulant-naïve octogenarian patients with non-valvular atrial fibrillation
af: Sugeon Park, et al.
Udgivet: (2020)

Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
af: V. A. Ionin, et al.
Udgivet: (2021)

ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
af: Alexey D. Ehrlich
Udgivet: (2018)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
af: Jun Qian, et al.
Udgivet: (2021)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
af: Alessandra M. Campos-Staffico, et al.
Udgivet: (2022)

Long term efficacy and safety of rivaroxaban plus cilostazol in the treatment of critical ischemia of the lower limbs in a frail, elderly patient with non valvular atrial fibrillation
af: Antonio Trani, et al.
Udgivet: (2020)

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation
af: Yang-Qi Pan, et al.
Udgivet: (2024)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
af: Yu-Sheng Lin, et al.
Udgivet: (2021)

Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable
af: D. A. Napalkov, et al.
Udgivet: (2018)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
af: N. A. Shatalova, et al.
Udgivet: (2023)

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
af: I. A. Zolotovskaya, et al.
Udgivet: (2021)

Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist
af: S. I. Farag, et al.
Udgivet: (2020)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
af: Nan Zhao, et al.
Udgivet: (2022)

SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS' VIEWPOINT
af: E. A. Drozdova
Udgivet: (2015)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
af: N. A. Novikova, et al.
Udgivet: (2016)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
af: Z. M. Safiullina, et al.
Udgivet: (2015)

SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS' VIEWPOINT
af: E. A. Drozdova
Udgivet: (2015)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
af: Z. M. Safiullina, et al.
Udgivet: (2015)

Risk Factors Associated with Cardioembolic Stroke in Patients with non Valvular Atrial Fibrillation
af: Daniel Guerra García, et al.
Udgivet: (2018)

Risk Factors Associated with Cardioembolic Stroke in Patients with non Valvular Atrial Fibrillation
af: Daniel Guerra García, et al.
Udgivet: (2018)